SPEEDX
SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific. The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005407/en/
“This partnership capitalises on the existing infrastructure of our two companies and the strength of our synergies,” said Colin Denver, SpeeDx CEO. “Our commitment to providing products and services that answer unmet clinical needs also extends to the pathology laboratories that are running our tests – in partnership with MolGen, we can address much of their workflow concerns and offer a more complete testing solution.”
Throughout the past year of COVID-19, in response to the increased demand for molecular testing workflow solutions, MolGen has developed a comprehensive offering including the PurePrep nucleic acid extraction portfolio, liquid handling instrumentation and other purpose-built automation to facilitate high-volume testing of SARS-CoV-2. SpeeDx complete the partnership with an initial offer of their CE-IVD SARS-CoV-2 test based on their proprietary Plex PCR® technology, allowing pathology laboratories a single point of contact to fulfil their testing needs.
“For MolGen, the collaboration with SpeeDx is a perfect example of combining the best of both worlds. Our DNA and RNA extraction solutions and automated workflow perfectly pair with SpeeDx diagnostic assay technology” said Maarten de Groot, MolGen CEO. “During the COVID pandemic adding the CE-IVD SARS-CoV-2 assay to our diagnostics portfolio is great opportunity to start our collaboration. And this is only the beginning of jointly building an innovative product portfolio”.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin, Texas and London, UK, with distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About MolGen
MolGen is global total solution provider of innovative extraction DNA / RNA technology, system, products and kits for human and animal diagnostics, the agriculture and biotech industries which reduce hands-on time and increase productivity while maintaining high yields and reproducibility.
From sample to result, MolGen is challenging the status quo in molecular diagnostics by offering platform stand-alone systems and consumables. Highly customizable, MolGen’s portfolio offers the perfect workflow for our customers’ specific needs, being high-quality, adaptable and safe.
Due to travel restrictions Maarten de Groot, MolGen CEO and Colin Denver, SpeeDx CEO joined a virtual session to officially announce the collaboration that will combine Molgen liquid handling and purpose-built automation with SpeeDx COVID-19 diagnostic solutions - extending a full workflow offering to pathology laboratories.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005407/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INNIO and KMW Secure Grid Stability and Data Center Supply With a Peaking Power Plant7.11.2025 09:00:00 CET | Press release
INNIO and KMW (Kraftwerke Mainz-Wiesbaden AG) are building a 54-MW peaking power plant for grid stabilization Additional safeguarding of the power supply for the “Green Rocks” data center project INNIO Group has signed a contract with KMW (Kraftwerke Mainz-Wiesbaden AG) for a new 54-MW peaking power plant. A total of twelve modular energy systems from INNIO are intended to be operated at the site. Part of the plant’s capacity is expected to be available for the “Green Rocks” data center, which is being built by KMW and Norwegian data center operator Green Mountain. INNIO’s decentralized energy solutions serve as backup in case of a blackout due to grid failure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107090386/en/ Visualization of the future Green Rocks data center (c) KMW The power plant is scheduled to be commissioned by the end of 2027. “The partnership between INNIO and KMW is a strategic milestone for energy s
Suzano Reports Increased Operational Efficiency With Lower Cash Cost in the Third Quarter of 20256.11.2025 23:58:00 CET | Press release
Ongoing improvement in cost competitiveness: cash production costs continue to reduce (down 7% Y-o-Y), due to the increased contribution from the Ribas do Rio Pardo unit. Continued progress in integrating recent acquisitions: Suzano Packaging reported its first positive Adjusted EBITDA from the US operations acquired one year ago. Suzano, the world’s largest pulp producer, announces its results for the third quarter of 2025 (3Q25), reporting sales of 3.6 million tonnes of pulp and paper combined, a 20% increase on the same quarter last year (3Q24). The positive result is driven by the operations of the Ribas do Rio Pardo pulp mill, inaugurated in 2024, and by the integration of paper production from assets acquired in the United States in October 2024. The cash cost of pulp production (excluding downtime) was R$801 per tonne, a 7% reduction compared to 3Q24, another positive highlight of the quarter. The results reflect the continuation of the downward trend in production costs and the
Vedanta Resources Launches CopperTech Metals to Bolster U.S. Copper Security and Advance Technology and Infrastructure Transformation6.11.2025 17:45:00 CET | Press release
CopperTech Metals Combines World-Class Konkola Mines' Copper and Cobalt Producing Heritage with Cutting-Edge Mining Technology and Artificial Intelligence to Advance U.S. Critical Mineral Independence and Serve America's Growing Infrastructure Needs$1.5 Billion Investment Program to Leverage Advanced Mining and Cutting-Edge AI-Driven Resource Identification and Extraction Technology to Propel Konkola's Operations into One of the Largest in the World Vedanta Resources Limited ("Vedanta") today announced the launch of CopperTech Metals Inc. ("CopperTech" or the "Company"), a U.S.-domiciled company with a mission to 'Power the Copper Century' and to bolster America's copper security needs while capitalizing on surging copper demand driven by artificial intelligence, data center expansion, grid modernization, defense technologies and industrial onshoring requirements. CopperTech will1 own and operate the Konkola Copper Mines in Zambia, one of the highest-grade copper producing assets in th
NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P®Services6.11.2025 17:11:00 CET | Press release
NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P Research Labs® (“Lab to Pharmacy”), further expanding its service portfolio, and bridging the translational research gap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106703527/en/ NJ Bio, Inc. now offers translational research services after completing asset purchase and full integration of the services of L2P® Research Labs, enhancing the discovery-to-development pipeline Currently, the attrition rate of biological molecules moving past phase 1 clinical trials is very high and the way to overcome this challenge is through translational research. NJ Bio specializes in preclinical and early-phase clinical research and development, with a primary focus on ADCs, bioconjugation, custom synthesis, oligonucleotides, and mRNAs. Howe
DevvStream Reports Fiscal Year 2025 Results and Advances Digital-Asset and Tokenization Strategy6.11.2025 17:01:00 CET | Press release
Company strengthens balance sheet, launches disciplined digital-asset treasury, and sets stage for acquisition-led growth in sustainability markets DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management and environmental-asset monetization firm, today announced financial results for its fiscal year ended July 31, 2025, and provided an update on strategic initiatives designed to enhance liquidity, expand technology capabilities, and position the Company for scalable, acquisition-driven growth. Fiscal 2025 Highlights Completed Nasdaq listing and de-SPAC transaction, establishing DevvStream as one of the few publicly traded pure plays in carbon and renewable-energy asset monetization. Closed initial $10 million tranche under the Helena $300 million convertible-note facility, providing liquidity to launch the Company’s digital-asset treasury. Reported initial revenue as the Company begins monetizing its environmental-asset pipeline. Successfully comple
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom